Healios K.K.

Overview

Healios K.K. ( heal Japan, Inc.) is a Japanese biotechnology company headquartered in Tokyo, Japan, focused on developing innovative regenerative medicine therapies using induced pluripotent stem cell (iPSC) technology [1](https://www.healios.co.jp/en/). The company is a pioneer in the Japanese iPSC research ecosystem and aims to deliver "cures and hope to patients with unmet medical needs" [2](https://www.healios.co.jp/en/).

Company Background

• Founded: 2011
• Headquarters: Tokyo, Japan
• Stock Exchange: TSE Mothers (4596)
• Focus: iPSC and somatic stem cell-based regenerative medicine

Focus Areas

Healios develops regenerative medicine products in two primary areas:

iPSC-Based Therapies

• Utilizing induced pluripotent stem cell technology
• Allogeneic (off-the-shelf) cell therapy products
• Focus on age-related diseases with high unmet medical needs

Somatic Stem Cell Therapies

• Using adult stem cells for tissue repair
• Acute care applications
• Trauma and critical illness treatment

Pipeline Products

Neurological Disorders

Ischemic Stroke

Healios is developing a somatic stem cell therapy for acute ischemic stroke, one of the leading causes of death and disability worldwide. This program aims to improve functional recovery in stroke patients through regenerative mechanisms.

Other Pipeline Programs

...

Overview

Healios K.K. ( heal Japan, Inc.) is a Japanese biotechnology company headquartered in Tokyo, Japan, focused on developing innovative regenerative medicine therapies using induced pluripotent stem cell (iPSC) technology [1](https://www.healios.co.jp/en/). The company is a pioneer in the Japanese iPSC research ecosystem and aims to deliver "cures and hope to patients with unmet medical needs" [2](https://www.healios.co.jp/en/).

Company Background

• Founded: 2011
• Headquarters: Tokyo, Japan
• Stock Exchange: TSE Mothers (4596)
• Focus: iPSC and somatic stem cell-based regenerative medicine

Focus Areas

Healios develops regenerative medicine products in two primary areas:

iPSC-Based Therapies

• Utilizing induced pluripotent stem cell technology
• Allogeneic (off-the-shelf) cell therapy products
• Focus on age-related diseases with high unmet medical needs

Somatic Stem Cell Therapies

• Using adult stem cells for tissue repair
• Acute care applications
• Trauma and critical illness treatment

Pipeline Products

Neurological Disorders

Stroke" style="color:#ccc;margin:1rem 0 0.4rem;font-size:0.9rem;font-weight:600">Ischemic Stroke

Healios is developing a somatic stem cell therapy for acute ischemic stroke, one of the leading causes of death and disability worldwide. This program aims to improve functional recovery in stroke patients through regenerative mechanisms.

Other Pipeline Programs

| Program | Technology | Indication | Status |
|---------|-------------|------------|--------|
| iPSC-AMD | iPSC | Age-Related Macular Degeneration | Preclinical/Clinical |
| iPSC-Liver | iPSC | Liver Disease | Research |
| iPSC-NK | iPSC | Solid Tumors | Research |
| Somatic Stem Cell | Adult stem cells | ARDS/Respiratory | Research |
| Somatic Stem Cell | Adult stem cells | Trauma | Research |

Scientific Approach

iPSC Technology

Healios utilizes iPSC technology to develop regenerative medicine therapies:

Cell Derivation: Generating pluripotent stem cells from patient or donor cells

Differentiation: Directing stem cells to become specific cell types needed for therapy

Quality Control: Rigorous testing to ensure safety and efficacy

Allogeneic Approach: Developing off-the-shelf products usable across patients

Manufacturing Platform

Healios has established a robust manufacturing platform for iPSC-based products:

• State-of-the-art cell culture facilities
• Scalable production methods
• Stringent quality control standards
• Compliance with Japanese regenerative medicine regulations

Neurodegeneration" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">Relevance to Neurodegeneration

While Healios' current primary focus is not directly on Alzheimer's or Parkinson's disease, their platform has significant relevance to neurodegeneration:

• iPSC Technology: iPSC-derived [neurons](/entities/neurons) can be used to model neurodegenerative diseases and screen potential therapeutics
• Stroke Program: Ischemic stroke shares common pathways with vascular dementia
• Regenerative Capacity: The platform technology can potentially be adapted for neurodegenerative conditions
• Neural Cell Therapy: Experience in neural differentiation could lead to future Parkinson's or Alzheimer's therapies
• Disease Modeling: iPSC technology enables patient-specific disease modeling for research

Leadership

Healios is led by experienced executives with backgrounds in:

• [Pharmaceutical](/companies) development
• iPSC research
• Cell therapy manufacturing
• Clinical development

Partnerships and Collaborations

Healios maintains collaborations with:

• Academic research institutions
• University hospitals for clinical trials
• [Pharmaceutical](/companies) partners for co-development

Regulatory Status

Healios operates under Japan's regenerative medicine framework, including:

• [Pharmaceutical](/companies) and Medical Device Act (PMD Act)
• Regenerative Medicine Promotion Act
• Conditional approval pathway for regenerative medicine products

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, Healios Official Website (n.d.)

Unknown, Healios Corporate Philosophy (n.d.)